We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Epic Sciences, Abramson Cancer Center Partner

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

"Successful treatment of cancer depends on understanding the heterogeneity of the patient's tumor burden and the driving genetic alterations behind disease progression," said Murali Prahalad, Ph.D., President and CEO of Epic Sciences. "Research conducted at the Abramson Cancer Center will enable faster development of novel personalized treatments that are able to address this heterogeneity."

The Epic Sciences no cell left behind® CTC detection and characterization platform is used to quantify the proteomic and genomic changes that accumulate in tumor cells over time and in response to successive rounds of therapy. Following a simple blood draw, the Epic Sciences platform can detect all categories of CTCs in the blood and identify, on a single cell basis, subpopulations of metastatic cancer cells that may be resistant or susceptible to cancer therapeutics. Currently, other technologies exclude many CTCs that do not adhere to assumptions about size or surface markers, which precludes a comprehensive view of the heterogeneity among a patient's tumor cells that may affect therapeutic response. The Epic Sciences platform has an unbiased detection approach in which all nucleated cells are analyzed.

The research teams at the Abramson Cancer Center, a leader in the liquid biopsy field for cancer detection, will use Epic Sciences' CTC detection and analysis platform to explore the heterogeneity of a diversity of cancer types, with a focus on genomic and phenotypic markers that help to better understand the utility of existing therapies and potential new drugs.

"Cancer is a complex, heterogeneous disease in which both genotype and phenotype change throughout progression," said Erica Carpenter, MBA, Ph.D., Director of the Circulating Tumor Material Laboratory and Research Assistant Professor in the Division of Hematology/Oncology at Penn. "We therefore need to utilize the most innovative technologies that allow us to study disease resistance."

Epic Sciences recently announced its platform's capability to subject a single CTC to both proteomic and genomic analyses, including deep sequencing of known cancer genes. The approach enables further precision to help evaluate early signs of drug resistance that could potentially influence therapy selection, including the use of combination therapies.